Novartis: will not exercise option on Surface's antibody
(CercleFinance.com) - Novartis has chosen to not purchase an option for Surface Oncology's SRF388, a human antibody that is believed to play a role on immuno-suppression and demonstrate anti-metastatic tumor activity.
Based on the terms of an agreement in 2016, Novartis had rights to purchase an option subject to certain financial conditions.
As a result, Surface will retain the global rights for its antibody.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Based on the terms of an agreement in 2016, Novartis had rights to purchase an option subject to certain financial conditions.
As a result, Surface will retain the global rights for its antibody.
Copyright (c) 2019 CercleFinance.com. All rights reserved.